LifeStance Health Group financials
$11.89+0.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $1.42B | $1.25B | $1.06B | $859.5M | $667.5M |
| Gross profit | $461.1M | $402.4M | $302.1M | $237.0M | $667.5M |
| Gross margin | 32.4% | 32.2% | 28.6% | 27.6% | 100.0% |
| Operating income | $24.0M | -$32.8M | -$189.3M | -$210.4M | -$286.4M |
| Net income | $9.7M | -$57.4M | -$186.3M | -$215.6M | -$343.9M |
| Net margin | 0.7% | −4.6% | −17.6% | −25.1% | −51.5% |
| Diluted EPS | $0.02 | $-0.15 | $-0.51 | $-0.61 | $-1.05 |
| EBITDA | $78.8M | $38.1M | -$108.9M | -$141.2M | -$232.2M |
| Operating cash flow | $146.2M | $107.3M | -$16.9M | $52.8M | $9.4M |
| Free cash flow | $110.0M | $85.7M | -$57.4M | -$26.5M | -$85.1M |
| Diluted shares | 391.1M | 379.1M | 367.5M | 355.3M | 327.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $248.6M | $154.6M | $78.8M | $108.6M | $148.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $265.9M | $279.8M | $280.3M | $225.1M | $157.4M |
| Total assets | $2.20B | $2.12B | $2.11B | $2.17B | $1.93B |
| Total liabilities | $682.9M | $672.0M | $681.0M | $655.1M | $382.1M |
| Shareholders' equity | $1.52B | $1.45B | $1.43B | $1.52B | $1.55B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology